Powell M F, Cleland J L, Eastman D J, Lim A, Murthy K, Newman M J, Nunberg J H, Weissburg R P, Vennari J C, Wrin T
Department of Pharmaceutical Research and Development, Genentech, Inc., South San Francisco, California 94080.
AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S105-8.
The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were significantly greater than the titers obtained in animals treated with alum. The use of QS21 shifted the dose-response curve, resulting in less MN rgp120 required to achieve equivalent titers to those in the alum formulations. The in vitro virus neutralizing (VN) titers from animals treated with QS21 were 3- to 10-fold higher than with alum. The data presented herein point to the superiority of QS21 as adjuvant in primates for MN rgp120.
通过使用狒狒优化了佐剂和免疫程序对HIV-1包膜糖蛋白MN rgp120免疫原性的影响。新型佐剂QS21比明矾佐剂引发血清转化更早，用QS21处理的动物对MN rgp120的抗体滴度显著高于用明矾处理的动物。QS21的使用使剂量反应曲线发生偏移，导致达到与明矾制剂相当滴度所需的MN rgp120更少。用QS21处理的动物的体外病毒中和（VN）滴度比用明矾处理的高3至10倍。本文提供的数据表明QS21作为灵长类动物中MN rgp120的佐剂具有优越性。
